Lymphoma clinical trials in Nevada

9 actively recruiting lymphoma trials at 5 sites across Nevada.

Data from ClinicalTrials.gov · last refreshed 2026-10-19

Phase 3 Recruiting Academic/Other

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT03150693

Sites in Nevada:

Carson Tahoe Regional Medical Center — Carson City, Nevada
Cancer and Blood Specialists-Henderson — Henderson, Nevada
Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
Las Vegas Cancer Center-Henderson — Henderson, Nevada

View on ClinicalTrials.gov →

Phase 3 Recruiting NIH

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06337318

Sites in Nevada:

OptumCare Cancer Care at Charleston — Las Vegas, Nevada
OptumCare Cancer Care at Fort Apache — Las Vegas, Nevada
Renown Regional Medical Center — Reno, Nevada

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group

NCT ID: NCT03959085

Sites in Nevada:

University Medical Center of Southern Nevada — Las Vegas, Nevada
Sunrise Hospital and Medical Center — Las Vegas, Nevada
Alliance for Childhood Diseases/Cure 4 the Kids Foundation — Las Vegas, Nevada
Summerlin Hospital Medical Center — Las Vegas, Nevada
Renown Regional Medical Center — Reno, Nevada

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06717347

Sites in Nevada:

OptumCare Cancer Care ( Site 0121) — Las Vegas, Nevada
Comprehensive Cancer Centers of Nevada ( Site 0113) — Las Vegas, Nevada
Cancer Care Specialists ( Site 9582) — Reno, Nevada

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT05947851

Sites in Nevada:

Renown Regional Medical Center-Renown Health Medical Oncology ( Site 5434) — Reno, Nevada

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Academic/Other

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…

Sponsor: PedAL BCU, LLC

NCT ID: NCT04726241

Sites in Nevada:

Alliance for Childhood Diseases/Cure 4 the Kids Foundation — Las Vegas, Nevada
Summerlin Hospital Medical Center — Las Vegas, Nevada
Renown Regional Medical Center — Reno, Nevada

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06124157

Sites in Nevada:

Alliance for Childhood Diseases/Cure 4 the Kids Foundation — Las Vegas, Nevada

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06317662

Sites in Nevada:

Alliance for Childhood Diseases/Cure 4 the Kids Foundation — Las Vegas, Nevada

View on ClinicalTrials.gov →

Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences

NCT ID: NCT06418204

Sites in Nevada:

OptumCare Cancer Care at Seven Hills — Henderson, Nevada
OptumCare Cancer Care at Charleston — Las Vegas, Nevada

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19